razaxaban has been researched along with Thrombosis in 6 studies
*Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexander, RS; Bai, S; Clark, CG; Ellis, CD; Han, Q; He, MY; Knabb, RM; Lam, PY; Li, R; Luettgen, JM; Pinto, DJ; Quan, ML; Sun, JH; Teleha, CA; Wexler, RR; Wong, PC | 1 |
| Bai, SA; Buriak, J; Cacciola, J; Fevig, JM; Knabb, RM; Lam, PY; Luettgen, JM; Rossi, KA; Wexler, RR; Wong, PC | 1 |
| Alexander, RS; Cheney, DL; He, K; King, SR; Knabb, RM; Lam, PY; Luettgen, JM; Qiao, JX; Rendina, AR; Smallwood, AM; Wexler, RR | 1 |
| Cheney, DL; Knabb, RM; Pinto, DJ; Smallheer, JM; Wexler, RR | 1 |
| Davis, B; Farndale, RW; Jarvis, GE; Koch, A; Pugh, N; Sakariassen, KS | 1 |
| Crain, EJ; Knabb, RM; Lam, PY; Quan, ML; Watson, CA; Wexler, RR; Wong, PC | 1 |
1 review(s) available for razaxaban and Thrombosis
| Article | Year |
|---|---|
Factor Xa inhibitors: next-generation antithrombotic agents.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Hemostasis; Humans; Models, Molecular; Protein Conformation; Structure-Activity Relationship; Thrombosis | 2010 |
5 other study(ies) available for razaxaban and Thrombosis
| Article | Year |
|---|---|
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Blood Proteins; Caco-2 Cells; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Imidazoles; Isoxazoles; Models, Molecular; Permeability; Protein Binding; Pyrazoles; Rabbits; Structure-Activity Relationship; Thrombosis | 2005 |
Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.
Topics: Administration, Oral; Animals; Antithrombin III; Biological Availability; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Pyrazoles; Pyrimidinones; Thrombosis | 2006 |
Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
Topics: Binding Sites; Biphenyl Compounds; Blood Coagulation; Cell Line, Tumor; Chemistry, Pharmaceutical; Cyclopropanes; Drug Design; Electrons; Factor Xa; Factor Xa Inhibitors; Humans; Kinetics; Models, Chemical; Models, Molecular; Molecular Conformation; Thrombosis | 2008 |
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; Isoxazoles; Male; Middle Aged; Perfusion; Pyrazoles; Surface Properties; Thromboplastin; Thrombosis; Young Adult | 2012 |
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Disease Models, Animal; Drug Therapy, Combination; Factor Xa; Fibrinolytic Agents; Hemorrhage; Hemostasis; Isoxazoles; Male; Platelet Aggregation; Pyrazoles; Rabbits; Thrombosis; Ticlopidine | 2007 |